Unlocking the quality-of-life preservation that exists in the earliest stages of diseases that affect women’s health, starting with breast cancer
An IVBH Company
Have you ever wanted to be a part of the future of breast cancer detection? At Mammogen, we're on a mission to revolutionize how breast cancer is found, and YOU could help make it happen. Our upcoming clinical trial is a groundbreaking opportunity to be at the forefront of this change. Click the link below to see if you're eligible and join us in shaping a world where breast cancer is detected earlier and more accurately than ever before. Together, we can make history!
About Us
We are a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency. Our mission is as important as it is blunt: To radically improve the detection, diagnosis and treatment of women’s health-related disease. We will create an end-to-never-end community for women around the world because we are in this together.
These words from Margaret Mead guide us:
"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has."
About Us
We are a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency. Our mission is as important as it is blunt: To radically improve the detection, diagnosis and treatment of women’s health-related disease. We will create an end-to-never-end community for women around the world because we are in this together.
These words from Margaret Mead guide us:
"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has."
Real Talk
There's so much more to our well-being than survival. It's about being ourselves. It's about thriving and empowerment.
We want more information, more sharing.
And we don’t want to be beholden to an old process--we want to be part of creating a new process. We want to stop focusing on remission as a benchmark for success. Because we know that the battle never ends.
We want to make things better. Detect earlier, diagnose easier, treat better. We want to be unreasonable about it. We want to stop accepting things for what they are and work to make them what they should be.
We will close the gap between science and support. Care, we believe should be more than end-to-end. It should come from an end-to-never-end community.
We want to talk about the fear, the anxiety, the depression, the marital challenges, the body-shame issues. No. We don't just want to talk about those things. We want to do something about them.
That’s what we’re building. Together. With you. And nobody will stand in our way. We never doubt that a small group of thoughtful, committed citizens can change the world.
We are those people.
Detect earlier.
The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA.
Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection.
Real Talk
There's so much more to our well-being than survival. It's about being ourselves. It's about thriving and empowerment.
We want more information, more sharing. And we don’t want to be beholden to an old process--we want to be part of creating a new process.
We want to stop focusing on remission as a benchmark for success. Because we know that the battle never ends.
We want to make things better. Detect earlier, diagnose easier, treat better. We want to be unreasonable about it. We want to stop accepting things for what they are and work to make them what they should be.
We will close the gap between science and support. Care, we believe should be more than end-to-end. It should come from an end-to-never-end community.
We want to talk about the fear, the anxiety, the depression, the marital challenges, the body-shame issues. No. We don't just want to talk about those things. We want to do something about them.
That’s what we’re building. Together. With you. And nobody will stand in our way. We never doubt that a small group of thoughtful, committed citizens can change the world.
We are those people.
Detect earlier.
The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA.
Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection.
Treat better.
While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer.
This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.
And now we can.
Treat better.
While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer.
This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.
And now we can.
For all women.
Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.
For all women.
Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.
From end-to-never-end.
We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do.
RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here.
We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.
From end-to-never-end.
We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do.
RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here.
We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.
Detect earlier.
The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA.
Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection.
Treat better.
While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer.
This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.
And now we can.
For all women.
Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.
From end-to-never-end.
We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do.
RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here.
We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.
The Here and Now
Mammogen’s flagship product is centered around breast cancer.
Our novel multi-gene expression signature for the non-invasive detection and diagnosis of breast cancer has been extensively validated in blood and saliva testing. It's positioned to unlock regular and reliable screening and diagnostic tools for tens of millions of women--women who are grossly--and unnecessarily--underserved by today's standard of care.
We're working to eliminate false negatives. That lets us get more women into screening earlier.
We're working to eliminate false positives so we can safely monitor women with suspicious nodules discovered by imaging.
We're working to do all of this. Regardless of how old you are, where you live, how much money you make, your genetics or your family history. That's our here and now. For you, made possible by all of us.
The Future
We are not stopping. What we're doing is too important.
We are working to develop, validate and commercialize our breakthrough liquid biopsy for breast cancer detection and confirmatory diagnosis. We are exploring other research and development projects, both within breast cancer, and other diseases that affect some-, most-, or only-women.
When women think about their health-- physical, mental and emotional--and the well-being of those they love, we want them to know that Mammogen, and the Mammogen community, is working with and for them. We want Mammogen to be the first, second and third thing that they think of.
With you, we want to be part of a thoughtful, committed group of citizens that will change the world.
Join us.
Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen
Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen
To learn more about our programs under development, please send us a note
Contact us
We will get back to you as soon as possible
Please try again later